Fulgent Genetics Inc (FLGT)

Fulgent Presents Updated FID-007 Data at ASCO 2026June 1, 2026 7:00 PM
Business Wire Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with established laboratory services and therapeutic development businesses, today announced it presented updated data in the Head and Neck Cancer Track during the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting Rapid Oral Abstract Session, scheduled from 4:30 p.m. to 6:00 p.m. CDT in Hall D1 at McCormick Place in Chicago. The abstract, entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020,” will present updated preliminary data from the Company’s open-label, randomized Phase 2 study (NCT06332092). The study is evaluating the efficacy of two dosing regimens and characterizing the pharmacokinetics, safety, and tolerability of FID-007 in combination with cetuximab in patients whose disease progressed following PD-1 based immune checkpoint inhibitor therapy. As of the April 16, 2026, data cutoff, FID-007 demonstrated meaningful clinical activity and a manageable safety profile in combination with cetuximab in this target patient population. The presentation slides with updated data will be available on Fulgent’s investor relations website at the conclusion of the presentation on June 1, 2026. Dr. Guilherme Rabinowits, one of the study’s Principal Investigators and a Senior Member in the Department of Head and Neck-Endocrine Oncology at Moffitt Cancer Center, said: “Patients with R/M HNSCC who progress after anti PD-1 based therapy lack an established, best second-line standard of care. In this setting, preliminary data showed encouraging clinical activity and a manageable safety profile for FID-007 in combination with cetuximab. The objective response rate was 61.9%, median progression-free survival was 6.7 months, median duration of response was 7.4 months, and one-year overall survival was 63.4%. Additionally, this combination showed activity in both human papilloma virus-related and -unrelated head and neck squamous cell carcinoma.” A Phase 3 study is planned. About Fulgent Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: future performance; Fulgent’s research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials, the expected timing of enrollment and regulatory filings for these trials and the availability of data or results of these trials and the potential future benefits of FID-007. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or Fulgent’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on Fulgent’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the success of Fulgent’s development efforts, including its ability to progress its candidates through clinical trials on the timelines expected; its compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and its ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. The forward-looking statements made in this press release speak only as of the date of this press release, and Fulgent assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Fulgent files reports filed with the U.S. Securities and Exchange Commission, or the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on Fulgent’s website upon their filing with the SEC. These reports contain more information about Fulgent, its business and the risks affecting their business. View source version on businesswire.com: https://www.businesswire.com/news/home/20260601448938/en/ Investor Relations Contact:
The Blueshirt Group
Lauren Sloane, Lauren@blueshirtgroup.com Original: Fulgent Presents Updated FID-007 Data at ASCO 2026

Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual MeetingMay 21, 2026 5:03 PM
Business Wire Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that its full abstract has been released on the ASCO 2026 website. The abstract will be presented within the Head and Neck Cancer Track of the American Society of Clinical Oncology (ASCO) Rapid Oral Abstract Session on June 1, 2026, from 4:30pm to 6:00pm (CDT) in Hall D1 of McCormick Place, Chicago. The abstract is entitled “FID-007 in combination with cetuximab in recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC), Abstract #6020”. It presents interim data from the Company’s open-label, randomized Phase 2 study (NCT06332092). The study was designed to evaluate the efficacy of two different dosing regimens and to characterize the pharmacokinetics (PK) and safety and tolerability of FID-007 in combination with cetuximab in patients with disease progression after treatment with PD-1-based immune checkpoint inhibitor. As of the data cut-off date of December 20, 2025, FID-007 exhibited meaningful clinical activity and a favorable safety profile when combined with cetuximab in target patient population. Key observations in the abstract include: FID-007 combined with cetuximab demonstrated anticancer activity at both dose levels for the 1L–2L treatment of R/M HNSCC. Of the 42 patients evaluable for efficacy, the objective response rate (ORR) was 60% (58% in Arm A, 61% in Arm B), and the median progression-free survival (mPFS) was 7.2 mo [6.7 mo in Arm A (95% CI: 2.0-12.8), and 7.2 mo in Arm B (95% CI: 4.0-NR)]. The median duration of response (DoR) was 7.4 mo (7.4 mo in Arm A, NR in Arm B) with 56% (14/25) of responders continuing to respond at the time of data cut-off. The overall survival data (OS) are immature at present. FID-007 exhibited a favorable safety and tolerability profile consisting mostly of grade 1-2 treatment-related adverse events (TRAEs). Grade 3-4 TRAEs occurring in ≥ 2 patients included neutropenia (3 in Arm A, 5 in Arm B), anemia (2 in Arm A, 4 in Arm B), leukopenia (3 in Arm B), acneiform dermatitis (2 in Arm A), maculo-papular rash and other rash (2 in Arm B). There was 1 Grade 5 TRAE (pneumonia in Arm B). The full abstract is now available on the ASCO® website, as well as on Fulgent’s investor relations website. The final presentation slides with updated data will be available on Fulgent’s investor relations website at the start of the session on June 1, 2026. Dr. Ray Yin, Co-Founder and President of Fulgent Pharma, said, “Based on available estimates, there are approximately 73,000 new head and neck Squamous Cell Carcinoma (HNSCC) cases in the U.S. and 930,000 worldwide each year, with 50% to 60% progressing to the recurrent or metastatic stage. We are encouraged by the clinical progress achieved so far and believe in the potential of FID-007 to serve as a meaningful treatment for R/M HNSCC patients, particularly given that the current standard of care offers a historical objective response rate (ORR) of just 5.8% to 19.1% and a progression-free survival (PFS) of only 2.3 to 3.7 months.” About Fulgent Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: future performance; Fulgent’s research and development efforts, including any implications that the results of earlier clinical trials will be representative or consistent with later clinical trials, the expected timing of enrollment and regulatory filings for these trials and the availability of data or results of these trials and the potential future benefits of FID-007. Forward-looking statements are statements other than historical facts and relate to future events or circumstances or Fulgent’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on Fulgent’s business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the success of Fulgent’s development efforts, including its ability to progress its candidates through clinical trials on the timelines expected; its compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and its ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events. The forward-looking statements made in this press release speak only as of the date of this press release, and Fulgent assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Fulgent files reports filed with the U.S. Securities and Exchange Commission, or the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on Fulgent’s website upon their filing with the SEC. These reports contain more information about Fulgent, its business and the risks affecting their business. View source version on businesswire.com: https://www.businesswire.com/news/home/20260521761872/en/ Investor Relations Contact:
The Blueshirt Group
Lauren Sloane, Lauren@blueshirtgroup.com
Original: Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting

Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026April 16, 2026 7:30 AM
Business Wire
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2026 financial results before the market opens on Friday, May 1, 2026. Management will host a conference call for the investment community the same day at 8:30 AM ET (5:30 AM PT) to discuss the results and answer questions.


The call may be accessed through a live audio webcast on the Investor Relations section of the Company’s website, http://ir.fulgentgenetics.com. An audio replay will be available at the same location.


About Fulgent


Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260416300061/en/
Investor Relations Contact:

The Blueshirt Group

Lauren Sloane, Lauren@blueshirtgroup.com

Source: Fulgent Genetics, Inc.


Original: Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026

Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDxMarch 17, 2026 4:31 PM
Business Wire
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced the completion of the acquisition of Bako Diagnostics, a premier pathology laboratory, and StrataDx, a premier dermatopathology laboratory, as previously announced on December 22, 2025.


Under the terms of the agreement, Fulgent acquired certain assets of Bako Diagnostics and acquired StrataDx for a total combined purchase price of approximately $56.9 million in cash, subject to certain post-closing adjustments.


For additional information, please refer to the Form 8-K that was filed with the SEC and is available at https://ir.fulgentgenetics.com/.


Advisors


Piper Sandler & Co. acted as exclusive financial advisor; and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. served as legal counsel to Fulgent Genetics, Inc. in connection with the transaction.


EV Health Partners acted as exclusive financial advisor, and Latham & Watkins LLP served as legal counsel to Consonance Capital Partners, Bako Diagnostics, and StrataDx.


About Fulgent Genetics


Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Fulgent aims to transform from a diagnostic business into a fully integrated precision medicine company.


About Bako Diagnostics


Bako Diagnostics is a premier national provider of specialty laboratory testing services which offers a comprehensive testing menu, including complete anatomic pathology services, proprietary molecular genetic testing, and peripheral neuropathy immuno-histochemical testing. Bako is primarily focused on providing clients with unmatched sector-specific expertise and physician support services.


About StrataDx


StrataDx is a national diagnostic laboratory located in Lexington, Massachusetts dedicated to providing best-in-class pathology services to save lives. Led by dermatopathology experts, StrataDx provides advanced diagnostics for a wide range of skin conditions including melanocytic and soft tissue lesions, dermatoses, and lymphomas. Board-certified oral pathologists represent decades of expertise across a wide range of clinical specialties. StrataDx is considered a leader in testing for the dermatology market.


About Consonance Capital Partners


Consonance Capital Partners is a private equity manager focused exclusively on investing in the healthcare industry.


Forward Looking Statements


This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: the efficiency or quality of services and testing, momentum, trajectory, vision, future opportunities and future growth of Fulgent’s testing and laboratory services, technologies and expansion, the future benefits of Fulgent’s research and development efforts, Fulgent’s identification and evaluation of opportunities and its ability to capitalize on opportunities, and Fulgent’s ability to continue to scale and grow its business.


Forward-looking statements are statements other than historical facts and relate to future events or circumstances or Fulgent’s future performance, and they are based on management’s current assumptions, expectations, and beliefs concerning future developments and their potential effect on Fulgent’s business, including the acquired businesses and assets of Bako Pathology and StrataDx. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: Fulgent’s level of success in establishing and obtaining the intended benefits from partnerships, strategic investments, joint ventures, other relationships or acquisitions and the risks related to potential assumed liability and integration challenges in connection with these partnerships, strategic investments, joint ventures, other relationships and acquisitions (which expressly include the Bako Diagnostics and StrataDx acquisitions); the market potential for, and the rate and degree of market adoption of, Fulgent’s tests (and following and assuming the completion of the acquisitions, Bako and StrataDx’s tests); Fulgent’s ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; Fulgent’s ability to maintain the low internal costs of its business model; Fulgent’s ability to maintain an acceptable margin; risks related to volatility in Fulgent’s results, which can fluctuate significantly from period to period; risks associated with the composition of Fulgent’s customer base, which can fluctuate from period to period and is often comprised of a small number of customers that account for a significant portion of Fulgent’s revenue; Fulgent’s level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests and testing services; the success of Fulgent’s development efforts, including Fulgent’s ability to progress its candidates through clinical trials on the timelines expected; Fulgent’s compliance with the various evolving and complex laws and regulations applicable to its business and its industry; and Fulgent’s ability to protect its proprietary technology and intellectual property. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.


The forward-looking statements made in this press release speak only as of the date of this press release, and Fulgent assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law. Fulgent’s reports filed with the U.S. Securities and Exchange Commission, or the SEC, including its annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 27, 2026, and the other reports it files from time to time, including subsequently filed annual, quarterly and current reports, are made available on Fulgent’s website upon their filing with the SEC. These reports contain more information about Fulgent, its business and the risks affecting its business.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260317221536/en/
Investor Relations Contact:

The Blueshirt Group

Lauren Sloane, Lauren@blueshirtgroup.com


Original: Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx

Fulgent Genetics Reports 2025 Financial Results and Issues 2026 GuidanceFebruary 27, 2026 10:04 AM
IH Market News
Fulgent Genetics (NASDAQ:FLGT) released its fourth-quarter and full-year 2025 results on February 27, 2026, reporting annual revenue growth of 14% to $322.7 million, while fourth-quarter revenue increased 9% year over year to $83.3 million. The company recorded GAAP net losses of $23.4 million for the quarter and $60.5 million for the full year, but generated non-GAAP profit of $5.2 million in Q4 and $13.2 million for 2025, supported by improving margins, expansion of AI- and digital pathology-driven laboratory services, and continued advancement of its oncology pipeline. During the year, FID-007 progressed through Phase 2 trials and FID-022 continued development in Phase 1.Management emphasized operational streamlining efforts, efficiency gains, and a strong liquidity position at year-end, with $705.5 million in cash and investments, excluding an anticipated tax refund. For 2026, the company expects revenue of approximately $350 million and forecasts a non-GAAP loss per share. Fulgent noted that insourcing activity by its largest customer will weigh on performance in the near term, although this impact could be partly or fully offset later in the year through contributions from the Bako and StrataDx acquisitions as well as ongoing strategic investments. The company said it remains confident in its longer-term growth outlook.More about Fulgent GeneticsFulgent Genetics, Inc. is a precision medicine company combining advanced technology with laboratory services and therapeutic development. Its laboratory segment provides diagnostic testing and physician-guided interpretation services, while its therapeutics division focuses on developing nanoencapsulated, targeted cancer treatments designed to enhance safety and effectiveness. The company is evolving from a diagnostics-focused organization toward a fully integrated precision medicine platform.Fulgent Genetics stock price

Original: Fulgent Genetics Reports 2025 Financial Results and Issues 2026 Guidance

FLGT one month

Might do a $100 bill here

In here for some off of Biden’s speech.

Even before the pandemic, Fulgent's market capitalization tripled in 2019 with 52% sales growth. Last year, COVID-19 pushed growth off the charts. Revenue rose 1,200% on the back of a 74-fold increase in testing volume. Beyond the numbers, the company established important relationships with state health departments, school systems, employers, and insurers.

The company ended the third quarter with $104 million cash and zero debt on its balance sheet.

Fulgent Genetics has also revised its fiscal 2020 revenue guidance from $135 million to $235 million on Nov. 9 and then to $300 million on Nov. 23, thanks to the ever-increasing demand for its COVID-19 tests.

I understand that the founder owns 30% of the stock BUT no debt, a big pile of cash and a strong technology base makes Fulgent a takeover target by some of th big guys in the genomics arena. Just thinking.
I would love to be in the middle of a bidding war!

This Board is dead! I own FLGT and expect a good quarter and a thriving business for a long time into the future.........but.......... enjoy NEWS like the last contract with the CDC.

The latest numbers suggest price to cash is 7 vs an industry 18. The revenue growth is projected to continue with Q1 projected at 77% of 2020. They just announced the CDC NGS contract - can we expect an upward revision of the Q1 revs?

All Weekly & Monthly SMA's are well below the current price. Closest one is at $70.60 - 20 SMA Weekly down to $15.49

Good quarter but book value and cash per share is 15 times & 40 times higher respectably. Way over valued imo

Total Cash (mrq) $74.94M
Total Cash Per Share (mrq) $3.09

Book Value Per Share (mrq) $8.02

Try $130.+

117.00 > pounding the table > 155.00 opening bell gap tomorrow!

FLGT

choo choo

Beautiful breakout of large Ascending Triangle Pattern. Have been holding FLGT for a long time but added last week as it was consolidating before it's next push up through the triangle. Love this stock...super long term hold for me. Diagnostic testing is always going to be important long after Covid is gone. Management team is tops and share structure is fantastic as earning surge...luv it!

Nice day here with $FLGT

FLGT what a ride from 6 bucks...took a long time but a massive play!!

FLGT one of the most exciting bio company's in GENOME testing...$30.27 next!!

FLGT long and strong..target reached!!!

FLGT here we go...this our long bio play for 2020!!!

Jumped back in $12.83....crazy pullback from $15's

If not you are only out 80 bucks. It's been awhile since I started trading again. I need to re-educate myself on options since its really based on speculation and I just don't have the depth of researching well enough to branch into options. Trying now to do this full-time, trying to keep it simple in the plethora of information that is the market. Like President Trump signaling no China deal until maybe after 2020 election. News "trumps" technical always. I love it though! JMHO

I trade call options for my "LOTTO" homeruns... very low cash with potential for huge returns.... so today I grabbed this friday AMRN $24 calls for .08 10 contracts total $80 bucks... If pdufa news comes early or we get a $35 buyout_ "dream"... then an $80 lotto is worth $10k....

So true, good way of putting it.

Base hits.... the homerun swingers have the highest strikeout ratio...

Thx Burp for keeping me informed. You're my best "favorites" follow. You know how to make money in the bios sector that's for sure. I'm still trying to catch runners before they run like everyone else. But 3-5-10% gains daily is fine with me.

growing sector...rising tide raises all ships thing

Thx Burp, is it because they are both in the genetics field? Some type of boiling over effect because FLGT might be bought too?

BOLD acquired for 100% premium $60 share After Hours....FLGT should get a good run....

https://finance.yahoo.com/m/15db9f96-d631-39e7-9d1d-a88160a6b0b9/this-gene-therapy-player-just.html?.tsrc=rss

13.30 to fill gap.

my pleasure.. btw $12.50

Thx burp

added @ $10.90

added 9.93 today eom

Jumped in 10.68...will add a little next week before PPS recovers...some are ignoring the guidance and that is just fine with me!

Will this company be bought out?

FLGT the future of disease prevention! GENOME testing will be the go to testing to see what markers you have and then early detection and treatment will up your chance for a long healthy life....but if you continue to eat poorly theres not much one can do!!

FLGT just a beauty...see ya a 18.41

* * $FLGT Video Chart 11-05-2019 * *

Link to Video - click here to watch the technical chart video

FLGT is getting ready to blow up with 13.18 up next!! Absolutely a beatiful set up!!

FLGT is back in action...long and strong. This ain’t over yet.

Genomics are the future. We will never cure cancer only prevent it.

The science looks good here to me.
Reminds me of early NVTA. Looking forward to seeing new highs again soon.

FLGT get ready for the bio sensation of the season.

FLGT ready to take on 13 buckaroos!!

Nice buying opportunity here today.

Got a piece of this nice looking pie.

FLGT what bio beast. The power of the chart and Genomics. Get ready to break the 13.00 range and head for the 14.00. A set up to dream about.